Moscow, September, 28 2006Quantum Pharmaceuticals and A.N. Belozersky Institute of Physico-Chemical Biology entered drug discovery collaboration aimed to discovery of novel small molecule inhibitors of HIV-1 integrase. HIV-1 integrase is one of the most promising targets in HIV drug discovery. Under the terms of the agreement Quantum Pharmaceuticals will apply its indystry leading drug discovery technology platform to identify novel classess of HIV-1 integrase inhibitors. The Institute is to evaluate the discovered compounds and contribute into its further research and development.
About Quantum Pharmaceuticals
Quantum Pharmaceuticals is a drug discovery company based in Moscow, Russia specializing in small molecule screening and design through the use of its proprietary technology platform.
